posted on 2020-01-15, 20:43authored byRafael Contreras-Montoya, Ylenia Jabalera, Víctor Blanco, Juan Manuel Cuerva, Concepcion Jimenez-Lopez, Luis Alvarez de Cienfuegos
Magnetite
nanoparticles (MNPs) are being used in a number of nanotechnological
applications, especially biomedical, both in diagnosis and in therapeutics
such as hyperthermia agents and as drug nanocarriers for targeted
chemotherapy. However, the development of efficient methodologies
to produce novel MNPs with the specific requirements needed for biomedical
applications is still challenging. In this context, biomimetic approaches
taking use of magnetosome proteins expressed as recombinant and/or
polyamino acids are becoming of great interest. In fact, these protocols
give rise to magnetite nanoparticles of adequate size, magnetic properties
and surface functionalization that make them compatible for biomedical
applications. In this respect, herein we show for the first time that
lysine (Lys), unlike other amino acids like arginine (Arg), is able
to exert a control over the size of MNPs produced in water and at
room temperature. This control occurs through the stabilization of
the magnetite nuclei by the lateral ammonium group of Lys. The strength
of such stabilization allows a further release of these previously
bonded nuclei to allow the further growth of the larger ones, thus
resulting in larger crystals compared to those obtained by using Arg
or no amino acids at all. MNPs obtained by the mediation of this amino
acid are fairly large (30 nm) while being superparamagnetic at room
temperature. They present an isoelectric point of 4, which may allow
the coupling/release of these MNPs to other molecules based on electrostatic
interaction, a large magnetic moment per particle and high magnetization
saturation. This study highlights the effects that biological additives
have in the process of magnetite biomineralization and goes along
the line of previous reports using magnetosome proteins and polyamino
acids.